Development of murine monoclonal antibodies to methamphetamine and methamphetamine analogues

被引:10
作者
Danger, Y
Gadjou, C
Devys, A
Galons, H
Blanchard, D
Folléa, G
机构
[1] Etab Francais Sang Pays Loire, F-44011 Nantes 01, France
[2] Univ Paris 05, Lab Chim Organ, Paris 2, France
[3] DB Biorun SARL, F-44300 Nantes, France
关键词
mAbs; methamphetamine; ecstasy; stereospecificity; affinity;
D O I
10.1016/j.jim.2005.10.017
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Methamphetamine and ecstasy are addictive drugs that cause major health problems in young people. Here we report on the development of high-affinity monoclonal antibodies to methamphetamine and its analogues, which may constitute powerful tools for antibody-based therapy. Six haptens, methamphetamine and ecstasy analogues, were synthesized, linked to a carrier protein and injected into mice. Several specific monoclonal antibodies were subsequently obtained following fusion of splenocytes from the immunized animals, with Sp2/O cells. Antibody specificity was fully investigated by competition ELISA, using a series of analogues, to identify specific amphetamine and/or ecstasy-specific antibodies. Antibody affinity was estimated to be in the range of 10(8) M-1 with an enantiomeric hapten. Finally, two characteristic hybridoma clones (DAS-M243-6H5 and DAS-M278-41312), secreting specific and potent mAbs were isolated. The development of drug-specific antibodies as in this study may provide promising therapeutic insight into how to neutralize methamphetamine in vivo during acute intoxication. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 38 条
[1]   Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET [J].
Buchert, R ;
Obrocki, J ;
Thomasius, R ;
Väterlein, O ;
Petersen, K ;
Jenicke, L ;
Bohuslavizki, KH ;
Clausen, M .
NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (08) :889-897
[2]   Overdose of 2.3 grams of intravenous methamphetamine: Case, analysis and patient perspective [J].
Buffum, JC ;
Shulgin, AT .
JOURNAL OF PSYCHOACTIVE DRUGS, 2001, 33 (04) :409-412
[3]   Agony and ecstasy: a review of MDMA effects and toxicity [J].
Burgess, C ;
O'Donohoe, A ;
Gill, M .
EUROPEAN PSYCHIATRY, 2000, 15 (05) :287-294
[4]   Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats [J].
Byrnes-Blake, KA ;
Laurenzana, EM ;
Carroll, FI ;
Abraham, P ;
Gentry, WB ;
Landes, RD ;
Owens, SM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 461 (2-3) :119-128
[5]   Generation of anti-(+) methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats [J].
Byrnes-Blake, KA ;
Carroll, FI ;
Abraham, P ;
Owens, SM .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (02) :329-338
[6]   SUPPRESSION OF PSYCHOACTIVE EFFECTS OF COCAINE BY ACTIVE IMMUNIZATION [J].
CARRERA, MRA ;
ASHLEY, JA ;
PARSONS, LH ;
WIRSCHING, P ;
KOOB, GF ;
JANDA, KD .
NATURE, 1995, 378 (6558) :727-730
[7]   Cocaine vaccines: Antibody protection against relapse in a rat model [J].
Carrera, MRA ;
Ashley, JA ;
Zhou, B ;
Wirsching, P ;
Koob, GF ;
Janda, KD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (11) :6202-6206
[8]   Venoms, antivenoms and immunotherapy [J].
Chippaux, JP ;
Goyffon, M .
TOXICON, 1998, 36 (06) :823-846
[9]   Amphetamine designer drugs - an overview and epidemiology [J].
Christophersen, AS .
TOXICOLOGY LETTERS, 2000, 112 :127-131
[10]   Development of monoclonal antibodies directed against cocaine and cocaethylene:: Potential new tools for immunotherapy [J].
Danger, Y ;
Devys, A ;
Gadjou, C ;
Galons, H ;
Blanchard, D ;
Folléa, G .
HYBRIDOMA AND HYBRIDOMICS, 2004, 23 (04) :212-218